Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales, Australia

Internal Medicine Journal

Volumn 43, Issue 4, 2013, Pages 402-410

  Kao, S C H ^a,b,c   Clarke, S ^c,d   Vardy, J ^b,c   Corte, P ^e   Clarke, C ^a   Van Zandwijk, N ^a,c  

^a Asbestos Diseases Research Institute   (Australia)

^b SYDNEY CANCER CENTRE   (Australia)

^c University of Sydney   (Australia)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Asbestos; Chemotherapy; Extrapleural pneumonectomy; Malignant pleural mesothelioma; Pattern of care; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; ASBESTOS; CALRETININ; CARCINOEMBRYONIC ANTIGEN; CD15 ANTIGEN; CYTOKERATIN 5; CYTOKERATIN 6; MESOTHELIN; THROMBOMODULIN; THYROID TRANSCRIPTION FACTOR 1; WT1 PROTEIN;

ADULT; AGED; ARTICLE; AUSTRALIA; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DUST EXPOSURE; FEMALE; HEALTH CARE UTILIZATION; HISTOLOGY; HUMAN; HUMAN TISSUE; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PATIENT CARE; PLEURA MESOTHELIOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THORACOSCOPY; THORAX RADIOGRAPHY;

AGED; AGED, 80 AND OVER; DUST; FEMALE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; NEW SOUTH WALES; OCCUPATIONAL EXPOSURE; PATIENT CARE; PHYSICIAN'S PRACTICE PATTERNS; PLEURAL NEOPLASMS; TREATMENT OUTCOME; WORKERS' COMPENSATION;

EID: 84875670728     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2012.02925.x     Document Type: Article

References (37)

1. Safe Work Australia. Mesothelioma in Australia: Incidence 1982 to 2007, Mortality 1997 to 2007. Canberra: Commonwealth of Australia; 2011.
2. Tracey E, Ling L, Baker D, Dobrovic A, Bishop J. Cancer in New South Wales: Incidence and Mortality 2007. Sydney: Cancer Institute New South Wales; 2009.
3. Leigh J, Driscoll T. Malignant mesothelioma in Australia, 1945-2002. Int J Occup Environ Health 2003; 9: 206-217.
4. Olsen N, Franklin P, Reid A, de Klerk N, Threlfall T, Shilkin K etal. Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation. Med J Aust 2011; 195: 271-274.
5. Driscoll T, Baker G, Daniels S, Lee J, Thompson R, Ferguson D etal. Clinical aspects of malignant mesothelioma in Australia. Aust N Z J Med 1993; 23: 19-25.
6. Australian Institute of Health and Welfare. Rural, Regional and Remote Health: Indicators of Health Status and Determinants of Health. Rural Health Series No. 9. Cat. No. PHE 97. Canberra: Commonwealth of Australia; 2008.
7. Stahel RA, Weder W, Felip E; On behalf of the ESMO Guidelines Working Group. Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19: ii43-44.
8. British Thoracic Society Standards of Care Committee. BTS statement on malignant mesothelioma in the UK, 2007. Thorax 2007; 62: ii1-19.
9. Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P etal. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for management of Malignant Pleural Mesothelioma. Eur Respir J 2010; 35: 479-495.
10. Page D, Fleming I, Fritz A, Balch C, Haller D, Morrow M. AJCC Cancer Staging Manual, 6th edn. New York: Springer; 2002.
11. Australian Bureau of Statistics. ASGC Remoteness Classification: Purpose and Use (Census Paper No. 03/01). Canberra: Commonwealth of Australia; 2003.
12. Tracey E, Kerr T, Dobrovic A, Currow D. Cancer in NSW: Incidence and Mortality Report 2008. Sydney: Cancer Institute New South Wales; 2010.
13. Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. J Occup Med 1992; 34: 718-721.
14. Hyland R, Ware S, Johnson A, Yates D. Incidence trends and gender differences in malignant mesothelioma in New South Wales, Australia. Scand J Work Environ Health 2007; 33: 286-292.
15. Yeung P, Rogers A. An occupation-industry matrix analysis of mesothelioma cases in Australia 1980-1985. Appl Occup Environ Hyg 2001; 16: 40-44.
16. Burdorf A, Dahhan M, Swuste P. Occupational characteristics of cases with asbestos-related diseases in The Netherlands. Ann Occup Hyg 2003; 47: 485-492.
17. Neumann V, Gunthe S, Mulle K, Fischer M. Malignant mesothelioma - German mesothelioma register 1987-1999. Int Arch Occup Environ Health 2001; 74: 383-395.
18. Metintas S, Metintas M, Ucgun I, Oner U. Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area. Chest 2002; 122: 2224-2229.
19. Bianchi C, Brollo A, Ramani L, Bianchi T, Giarelli L. Asbestos exposure in malignant mesothelioma of the pleura: a survey of 557 cases. Ind Health 2001; 39: 161-167.
20. Yeung P, Patience K, Apthorpe L, Willcocks D. An Australian study to evaluate worker exposure to chrysotile in the automotive service industry. Appl Occup Environ Hyg 1999; 14: 448-457.
21. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P etal. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644.
22. Hollen P, Gralla R, Liepa A, Symanowski J, Rusthoven J. Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso. Support Care Cancer 2006; 14: 11-21.
23. Bydder S, Phillips M, Joseph DJ, Cameron F, Spry NA, DeMelker Y etal. A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br J Cancer 2004; 91: 9-10.
24. O'Rourke N, Garcia JC, Paul J, Lawless C, McMenemin R, Hill J. A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol 2007; 84: 18-22.
25. Boutin C, Rey F, Viallat J-R. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. Chest 1995; 108: 754-758.
26. Treasure T, Lang-Lazdunski L, Waller D, Bliss J, Tan C, Entwisle J etal. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 2011; 12: 763-772.
27. Weder W, Stahel R, Baas P, Dafni U, de Perrot M, McCaughan B etal. The MARS feasibility trial: conclusions not supported by data. Lancet Oncol 2011; 12: 1093-1094.
28. Flores R, Riedel E, Donington J, Alago W, Ihekweazu U, Krug L etal. Frequency of use and predictors of cancer-directed surgery in the management of malignant pleural mesothelioma in a community-based (Surveillance, Epidemiology, and End Results [SEER]) population. J Thorac Oncol 2010; 5: 1649-1654.
29. Spirtas R, Connelly RR, Tucker MA. Survival patterns for malignant mesothelioma: the seer experience. Int J Cancer 1988; 41: 525-530.
30. Lee C, Murray N, Anderson H, Rao S, Biship W. Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia. Lung Cancer 2009; 64: 308-313.
31. Chapman A, Mulrennan S, Ladd B, Muers M. Population based epidemiology and prognosis of mesothelioma in Leeds, UK. Thorax 2008; 63: 435-439.
32. Nowak AK, Stockler MR, Byrne MJ. Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the European organization for research and treatment of cancer core quality of life questionnaire and lung cancer module. J Clin Oncol 2004; 22: 3172-3180.
33. Lee S, O'Connor M, Chapman Y, Hamilton V, Francis K. A very public death: dying of mesothleioma and asbestos-related lung cancer (M/ARLC) in the Latrobe Valley, Victoria, Australia. Rural Remote Health 2009; 9: 1183.
34. Hawley R, Monk A. Malignant mesothelioma: current practice and research directions. Collegian 2004; 11: 22-26.
35. Husain A, Colby T, Ordonez N, Krausz T, Borczuk A, Cagle P etal. Guidelines for pathologic diagnosis of malignant mesothelioma. A consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009; 133: 1317-1331.
36. Klebe S, Nurminen M, Leigh J, Henderson D. Diagnosis of epithelial mesothelioma using tree-based regression analysis and a minimal panel of antibodies. Pathology 2009; 41: 140-148.
37. Kao S, Griggs K, Lee K, Armstrong N, Clarke S, Vardy J etal. Validation of the use of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma. Pathology 2010; 43: 313-317.